citrafleet oral powder 16.11g sachets
casen recordati s.l. - sodium picosulfate; citric acid monohydrate; magnesium oxide light - oral powder - 10mg ; 12gram ; 3.5gram
signifor solution
recordati rare diseases canada inc - pasireotide (pasireotide diaspartate) - solution - 0.3mg - pasireotide (pasireotide diaspartate) 0.3mg - somatostatin agonists
signifor solution
recordati rare diseases canada inc - pasireotide (pasireotide diaspartate) - solution - 0.6mg - pasireotide (pasireotide diaspartate) 0.6mg - somatostatin agonists
signifor solution
recordati rare diseases canada inc - pasireotide (pasireotide diaspartate) - solution - 0.9mg - pasireotide (pasireotide diaspartate) 0.9mg - somatostatin agonists
carbaglu tablet for suspension
recordati rare diseases - carglumic acid - tablet for suspension - 200mg - carglumic acid 200mg - ammonia detoxicants
cystadane- betaine powder, for solution
recordati rare diseases - betaine (unii: 3scv180c9w) (betaine - unii:3scv180c9w) - betaine 1 g in 1 g - cystadane ® is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. included within the category of homocystinuria are: - cystathionine beta-synthase (cbs) deficiency - 5,10-methylenetetrahydrofolate reductase (mthfr) deficiency - cobalamin cofactor metabolism (cbl) defect none. risk summary available data from a limited number of published case reports and postmarketing experience with cystadane use in pregnancy have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with betaine. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnanc
mustargen mechlorethamine hydrochloride powder for solution
recordati rare diseases, inc. - mechlorethamine hydrochloride (unii: l0mr697hhi) (mechlorethamine - unii:50d9xsg0vr) - mechlorethamine hydrochloride 10 mg in 10 ml
signifor lar powder for suspension, sustained-release
recordati rare diseases canada inc - pasireotide (pasireotide pamoate) - powder for suspension, sustained-release - 20mg - pasireotide (pasireotide pamoate) 20mg - somatostatin agonists
signifor lar powder for suspension, sustained-release
recordati rare diseases canada inc - pasireotide (pasireotide pamoate) - powder for suspension, sustained-release - 60mg - pasireotide (pasireotide pamoate) 60mg - somatostatin agonists
signifor lar powder for suspension, sustained-release
recordati rare diseases canada inc - pasireotide (pasireotide pamoate) - powder for suspension, sustained-release - 40mg - pasireotide (pasireotide pamoate) 40mg - somatostatin agonists